Incidence of malignancy in multiple sclerosis: A cohort study in the Danish Multiple Sclerosis Registry

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,2 MB, PDF-dokument

  • Mette Nørgaard
  • Katalin Veres
  • Sellebjerg, Finn Thorup
  • Lise S. Svingel
  • Caroline Foch
  • Emmanuelle Boutmy
  • Meritxell Sabidó
  • Melinda Magyari

Background: The association between multiple sclerosis and malignancy is controversial and a current appraisal is needed. Objective: To determine the incidence of malignancy in patients with multiple sclerosis compared with the general population and in relation to disease-modifying therapy. Methods: Patients with multiple sclerosis (1995 – 2015) were matched by birth year and sex to individuals without multiple sclerosis in the general population. Patients with multiple sclerosis initiating disease-modifying therapy were evaluated using landmark period analysis. Malignancy risk was assessed by incidence rates, incidence rate ratios, and standardised incidence ratios. Results: The standardised incidence ratio of any malignancy (excluding non-melanoma skin cancer) in patients with multiple sclerosis (n = 10,557) was 0.96 (95% CI 0.88 – 1.06), and there was no increased incidence of specific malignancy types compared with the general population cohort (n = 103,761). At the 48-month landmark period, the age-adjusted incidence per 100,000 person-years of any malignancy (excluding non-melanoma skin cancer) was 436.7 (95% CI 361.0 – 512.4) in patients newly treated with immunomodulator-only and 675.1 (95% CI 130.4 – 1219.9) in patients newly treated with immunosuppressant-only. Conclusions: There was no increased incidence of malignancy overall or by type in patients with multiple sclerosis compared neither with the general population nor in relation to disease-modifying therapy.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis Journal - Experimental, Translational and Clinical
Vol/bind7
Udgave nummer4
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
MN, KV and LSS are salaried employees of Aarhus University/Aarhus University Hospital. The study was partially funded by the healthcare business of Merck KGaA, Darmstadt, Germany as a research grant given to and administered by Aarhus University, Denmark. CF, EB and MS are full-time employees of the healthcare business of Merck KGaA, Darmstadt, Germany. FS has served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, the healthcare business of Merck KGaA (Darmstadt, Germany), Novartis, Roche, Sanofi-Genzyme and Teva. MM has served on the scientific advisory board for AbbVie, Alexion, Biogen, the healthcare business of Merck KGaA (Darmstadt, Germany), Novartis, Roche and Sanofi, and has received honoraria for lecturing from Biogen, the healthcare business of Merck KGaA (Darmstadt, Germany), Novartis and Sanofi, and has received support for congress participation from Biogen, Genzyme, the healthcare business of Merck KGaA (Darmstadt, Germany) and Roche.

Funding Information:
The current analysis administered by Aarhus University was partly funded by a research agreement from the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). Merck contributed to the design and the protocol of the study but the academic authors made the final determination on which analyses to present and how best to interpret them.

Funding Information:
Medical writing assistance was provided by Farah Johnson-May and Ella Palmer of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Merck Healthcare KGaA, Darmstadt, Germany.

Publisher Copyright:
© The Author(s), 2021.

ID: 303772685